Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.66 USD | -4.32% | +4.31% | -35.83% |
Mar. 19 | Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating | MT |
Mar. 18 | Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 25.86M | Capitalization | 68.1M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -69M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.63 x |
P/E ratio 2024 * |
-1.18
x | P/E ratio 2025 * |
-1.79
x | Employees | 54 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.87% |
Latest transcript on Leap Therapeutics, Inc.
1 day | -4.32% | ||
1 week | +4.31% | ||
Current month | -4.66% | ||
1 month | -6.67% | ||
3 months | -44.35% | ||
6 months | +90.00% | ||
Current year | -35.83% |
Managers | Title | Age | Since |
---|---|---|---|
Doug Onsi
CEO | Chief Executive Officer | 55 | 10-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Jason Baum
CTO | Chief Tech/Sci/R&D Officer | 45 | 20-08-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
BRD | Director/Board Member | 72 | 15-12-31 |
Nissim Mashiach
BRD | Director/Board Member | 63 | 16-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.66 | -4.32% | 192,513 |
24-03-27 | 2.78 | +12.10% | 191,777 |
24-03-26 | 2.48 | +3.33% | 101,183 |
24-03-25 | 2.4 | -4.76% | 276,900 |
24-03-22 | 2.52 | -1.18% | 107,881 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.83% | 68.1M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |